Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.31 -5.8%	$1.36	$0.86 ▼ $3.36	$84.20M	0.14	248,281 shs	273,980 shs
ADCT ADC Therapeutics	$3.25 +0.8%	$2.97	$1.05 ▼ $3.97	$362.25M	1.92	712,621 shs	724,346 shs
CTMX CytomX Therapeutics	$2.05 -1.0%	$2.25	$0.40 ▼ $3.10	$341.37M	2.13	3.92 million shs	1.58 million shs
INBX Inhibrx Biosciences	$27.88 +1.8%	$21.24	$10.81 ▼ $28.16	$396.89M	0.24	103,597 shs	126,178 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-5.76%	-3.68%	-5.07%	+28.43%	-52.71%
ADCT ADC Therapeutics	+0.62%	+4.51%	+12.87%	+4.68%	+10.75%
CTMX CytomX Therapeutics	-0.97%	+0.99%	-8.89%	-18.65%	+76.72%
INBX Inhibrx Biosciences	+1.75%	+15.40%	+14.92%	+105.60%	+99.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.2092 of 5 stars	3.5	5.0	0.0	2.3	1.7	0.6
ADCT ADC Therapeutics	1.3679 of 5 stars	3.5	1.0	0.0	0.6	0.8	0.6
CTMX CytomX Therapeutics	4.2179 of 5 stars	3.5	1.0	4.7	2.8	1.7	1.3
INBX Inhibrx Biosciences	1.6424 of 5 stars	0.0	3.0	4.6	2.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$7.00	434.35% Upside
ADCT ADC Therapeutics	3.00	Buy	$7.75	138.83% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	180.49% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABOS, INBX, ADCT, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ABOS Acumen Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $9.00
8/22/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
ADCT ADC Therapeutics	$70.84M	5.15	N/A	N/A	($1.77) per share	-1.83
CTMX CytomX Therapeutics	$138.10M	2.45	$0.36 per share	5.72	$0.73 per share	2.81
INBX Inhibrx Biosciences	$1.40M	288.46	$121.22 per share	0.23	$4.73 per share	5.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	11/11/2025 (Estimated)
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.66	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	-$10.58	N/A	N/A	N/A	N/A	-137.83%	-76.31%	11/13/2025 (Estimated)

Latest ABOS, INBX, ADCT, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	-$1.85	+$1.07	-$1.85	N/A	$1.30 million
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
ADCT ADC Therapeutics	N/A	4.93	4.66
CTMX CytomX Therapeutics	N/A	4.20	4.20
INBX Inhibrx Biosciences	1.45	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ADCT ADC Therapeutics	41.10%
CTMX CytomX Therapeutics	67.77%
INBX Inhibrx Biosciences	82.46%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
ADCT ADC Therapeutics	5.40%
CTMX CytomX Therapeutics	6.60%
INBX Inhibrx Biosciences	17.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
INBX Inhibrx Biosciences	166	14.49 million	12.01 million	Optionable

ABOS, INBX, ADCT, and CTMX Headlines

Recent News About These Companies

Groupe la Francaise Purchases New Position in Inhibrx Biosciences, Inc. $INBX

August 27 at 5:56 AM | marketbeat.com

Inhibrx Biosciences Reports Q2 2025 Financial Results

August 26 at 12:10 AM | tipranks.com

Inhibrx Biosciences (NASDAQ:INBX) Receives Market Perform Rating from JMP Securities

August 25, 2025 | americanbankingnews.com

Inhibrx Biosciences' (INBX) "Market Perform" Rating Reiterated at JMP Securities

August 24, 2025 | marketbeat.com

HighTower Advisors LLC Acquires 90,002 Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX)

August 19, 2025 | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to "Hold" Rating

August 19, 2025 | americanbankingnews.com

Inhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to Hold Rating

August 18, 2025 | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Releases Earnings Results, Beats Estimates By $1.07 EPS

August 15, 2025 | marketbeat.com

Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

XTX Topco Ltd Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

August 14, 2025 | marketbeat.com

Inhibrx Reports Second Quarter 2025 Financial Results

August 13, 2025 | prnewswire.com

Inhibrx Biosciences (INBX) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer

July 29, 2025 | msn.com

Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype

July 18, 2025 | seekingalpha.com

Noteworthy Tuesday Option Activity: INBX, ODP, AZO | Nasdaq

July 10, 2025 | nasdaq.com

INBX - Inhibrx Biosciences Inc Executives - Morningstar

July 2, 2025 | morningstar.comM

Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Inhibrx Biosciences Inc (INBX) - Investing.com

June 25, 2025 | investing.com

Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President

April 3, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, INBX, ADCT, and CTMX Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.31 -0.08 (-5.76%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.05 (+3.51%)

As of 07:20 AM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ADC Therapeutics NYSE:ADCT

$3.24 +0.03 (+0.78%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$3.26 +0.02 (+0.62%)

As of 08/28/2025 07:59 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

CytomX Therapeutics NASDAQ:CTMX

$2.05 -0.02 (-0.97%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$2.03 -0.02 (-0.78%)

As of 07:00 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Inhibrx Biosciences NASDAQ:INBX

$27.88 +0.48 (+1.75%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$27.88 0.00 (0.00%)

As of 08/28/2025 04:32 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time